INVO News and Press, INVO BioScience Inc. From 04/17/23

2023-04-17 19:01:05 ET INVO Bioscience, Inc. (INVO) Q4 2022 Earnings Conference Call April 17, 2023, 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Steven Shum - Chief Executive Officer Andrea Goren - Chief Financial Officer ...

2023-04-17 16:12:28 ET INVO BioScience press release ( NASDAQ: INVO ): FY GAAP EPS of -$0.90 misses by $0.05 . Revenue of $0.8M (-80.8% Y/Y). Selling, general and administrative expenses for the years ended December 31, 2022 and 2021 were $10.6 million and $9.0 mil...

INVO Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , April 17, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a comme...

INVO Bioscience to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Monday, April 17, 2023 PR Newswire Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , April 11, 2023 ...

INVO Congratulates Wisconsin Fertility Institute on Being Named One of America's Best Fertility Clinics by Newsweek PR Newswire INVO recently announced the signing of binding agreements to acquire this top-rated clinic SARASOTA, Fla. and MADISON, Wis. , A...

2023-03-31 09:13:06 ET INVO Bioscience ( NASDAQ: INVO ) said it expects Q4 total revenue to reflect a sequential increase of approximately 15% to 19%, or to between $270K and $280K, above analysts estimate of $257.50K. "Looking forward, we are thrilled with the March 2023 sign...

INVO Provides Preliminary Update on FY2022 Financial Results PR Newswire SARASOTA, Fla. , March 30, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced t...

INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering PR Newswire SARASOTA, Fla. , March 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding acce...

2023-03-24 08:22:49 ET INVO Bioscience ( NASDAQ: INVO ) entered into a securities purchase agreement with a single healthcare focused institutional investor to purchase 3.68M shares in a registered direct offering. In a concurrent private placement, it has also a...

INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market PR Newswire SARASOTA, Fla. , March 24, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focu...